Received May 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 1 | — | — |
No additional AE; the patient was administered this dose via a feeding tube (nasogastric); patient received their first dose of ROTATEQ on 4/11/2025 at the age of 18 weeks and 4 days.; This spontaneous report was received from a Nurse (registered nurse [RN]) and refers to an 18-week-old female patient. The patient's medical history, concurrent conditions, and concomitant therapies were not reported. On 11-Apr-2025 (at the age of 18 weeks and 4 days), the patient was vaccinated with the first dose of Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ), Oral solution, dose number 1, administered via a feeding tube (nasogastric) (exact dose, lot # and expiration date were not reported) for prophylaxis at Clinic (inappropriate schedule of product administration, incorrect route of product administration). No additional adverse event (AE) was reported (no adverse event). Lot # is being requested and will be submitted if received.